Blog | folioconsultinggroup

Your IDE Approval Does Not Validate Your PMA Clinical Endpoint — Here's What Does

IDE approval confirms your study is safe to proceed. It does not validate your PMA primary endpoint or evidence standard. Here's how to close the gap before your pivotal trial.

4 min read

Breakthrough Device Designation: What It Gets You and What It Doesn't

BDD accelerates FDA engagement and collaboration — it does not lower the evidentiary bar. Here's how to build a regulatory strategy around what it actually does.

4 min read

Using AI to Draft FDA Submission Content: The Risks That Will Catch You at Review

AI-generated regulatory documentation looks polished but introduces specific failure modes FDA reviewers will identify.

4 min read

Are you pressed for time?

Reach out to discuss our priority project pricing.

Schedule Consultation

With a deep understanding of regulatory requirements, we make premarket submissions easy.

Click to schedule a free 30 minute initial consultation to see how we can help craft your regulatory strategy.

Schedule Consultation